Compare Crispr Therapeutics AG (CRSP) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs MINISO Group Holding Ltd — how do they compare? Crispr Therapeutics AG trades at $54.07 (market cap $5.23B), while MINISO Group Holding Ltd trades at $12.03 (market cap $3.62B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MNSO | |
|---|---|---|
Market Cap | $5.23B | $3.62B |
Sector | Health | Technology |
52-Week High | $76.78 | $26.63 |
52-Week Low | $44.34 | $11.30 |
Enterprise Value | $3.65B | $4.29B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MNSO trades at $12.55, showing minimal daily movement (-0.08%). The stock exhibits neutral technical signals with bearish moving averages, trading near key support at $12. Fundamentally, the company reported strong Q1 2026 earnings that beat expectations with 28.5% revenue growth, though recent quarters showed mixed results. The company announced a HK$2 billion share repurchase program in June 2026, signaling management confidence in undervalued shares.
MNSO presents a compelling value opportunity with attractive valuation ratios (P/E 12.65, P/S 1.15) and improving profitability (2026 net margin projected at 8.98%). However, investors face risks from margin compression and volatile quarterly performance. With 75% analyst buy ratings and technical support at current levels, the stock offers upside potential but requires monitoring of execution consistency and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
